Obstetrics & Gynaecology

Gestational Diabetes Mellitus

Also known as Gestational diabetes mellitus · GDM · Hyperglycaemia first detected in pregnancy

A source-verified, region-aware guide to gestational diabetes: distinguish GDM from overt diabetes, keep WHO/IADPSG, ACOG and NICE pathways separate, individualise lifestyle and pharmacotherapy, plan fetal surveillance and birth, protect the newborn, and complete postpartum prevention and future-pregnancy care.

High yieldHigh evidenceUpdated 27 July 202610 min readVerification in progress

Practise this topic

Plate IFigure from this chapter
On this page
Study tools

Practise this topic

Exam tags

NEET-PGINICETUSMLEPLAB

Red flags

  • Hyperglycaemia meeting non-pregnant diabetes thresholds may represent overt diabetes in pregnancy, not GDM; confirm and manage through the pre-existing-diabetes pathway
  • Do not mix WHO/IADPSG one-step, ACOG two-step and NICE risk-based thresholds
  • Insulin is preferred first-line pharmacotherapy in ADA/ACOG practice; NICE usually offers metformin after a lifestyle trial, with defined immediate-insulin exceptions
  • 40% neonatal dextrose gel 200 mg/kg equals 0.5 mL/kg, not 0.2 mL/kg; IV glucose follows the local neonatal protocol
  • Postpartum testing differs: ADA 75 g OGTT at 4 to 12 weeks; NICE fasting plasma glucose at 6 to 13 weeks

1. Definition: first separate GDM from overt diabetes

Modern classification distinguishes diabetes mellitus in pregnancy from GDM. WHO's live IRIS diagnostic authority classifies hyperglycaemia in pregnancy as diabetes in pregnancy when it meets the non-pregnant diagnostic thresholds for fasting or post-load plasma glucose, or random glucose with classic symptoms; absent unequivocal hyperglycaemia, confirm an abnormal diagnostic result. Lower pregnancy-specific hyperglycaemia may meet GDM criteria instead. HbA1c can support recognition of pre-existing diabetes, but HbA1c alone is neither a universal booking screen nor the routine diagnostic test for GDM.[1]

The distinction matters because organogenesis has already occurred by routine GDM testing. Overt diabetes requires urgent specialist review for glucose treatment, retinal/renal assessment and fetal structural evaluation. Immediately review chronic medicines and, in line with NICE NG3, stop ACE inhibitors/ARBs and statins as soon as pregnancy is confirmed, substituting pregnancy-compatible treatment where needed.[15]

2. Who and when to test

Routine testing is usually performed in the late second trimester: in the HAPO dataset underpinning the IADPSG criteria, participants underwent the 75 g OGTT between 24 and 32 weeks of gestation. Diagnostic strategy varies by service—the United States commonly uses the two-step approach, whereas one-step fasting-based testing with a 75 g load underpins the IADPSG criteria—and some services select who is tested using risk factors rather than a universal challenge (NICE NG3). The pathway chosen by the local service determines both sampling and thresholds.[8][18]

Risk factors include previous GDM, previous macrosomic infant, higher BMI using locally appropriate ethnicity-sensitive thresholds, first-degree family history of diabetes and higher-risk ethnic background. NICE NG3 also uses glycosuria 2+ once or 1+ on two or more occasions as a reason to consider further testing. Risk factors never justify borrowing thresholds from another pathway.[9]

Early-pregnancy testing primarily seeks previously unrecognised pregestational diabetes. The thresholds, benefits and harms of diagnosing and treating milder GDM before 24 weeks remain less certain. TOBOGM found a modest improvement in a composite neonatal outcome with immediate treatment in a selected early-GDM population, but this does not make one early-GDM algorithm universal. If early testing is normal, people still eligible for routine testing are retested at 24 to 28 weeks according to local guidance.[10][11]

3. Three diagnostic pathways—keep each intact

Reader-visible authorities: WHO 2013 diagnostic classification, NICE NG3 recommendations, ADA Standards of Care 2026, and the ACOG 2024 screening update.[1][10][15]

FigureUse one complete pathway without mixing thresholds. WHO/IADPSG: one-step testing with any one of three thresholds. US two-step: screen first, then a fasting diagnostic OGTT, usually requiring more than one abnormal value. NICE: risk-factor selection directly to a two-hour OGTT. Overt diabetes sits outside GDM.
The UK panel follows NICE NG3.[1][9]

WHO / IADPSG

Perform a fasting 75 g OGTT. Diagnose GDM when any one value is met: fasting ≥5.1 mmol/L, 1 hour ≥10.0 mmol/L, or 2 hours ≥8.5 mmol/L, provided overt-diabetes thresholds are not met.[8]

US — ACOG two-step

First perform a non-fasting 50 g 1-hour glucose challenge. If the local screen threshold is positive, perform a fasting 100 g 3-hour OGTT. Diagnosis on the two-step pathway usually requires two or more abnormal values, using the laboratory's named criteria; do not import the WHO “any one” rule.[18]

UK — NICE

Offer a risk-factor–based diagnostic OGTT to people meeting NICE NG3 risk-factor criteria, who are tested directly without a preceding challenge. Follow NG3 for its named sampling schedule and diagnostic thresholds; do not import them from another pathway. International strategies genuinely differ in which samples are taken and which cutoffs are used.[18]

[18]

The HAPO study included 25,505 pregnancies at 15 centres in nine countries and found continuous associations between maternal glucose and outcomes without an obvious natural threshold. Associations differed by endpoint: fasting glucose was strongest for high cord C-peptide, whereas 1-hour glucose was strongest for birthweight above the 90th centile. IADPSG converted those continuous data into pragmatic thresholds, so a diagnostic cut-off is a policy boundary rather than a biological cliff.[3][1]

4. Pathophysiology and outcomes

FigureGDM reflects an inadequate compensatory increase in maternal insulin secretion relative to rising pregnancy insulin resistance—not an obligatory absolute fall in beta-cell output. Maternal glucose crosses through placental transporters; maternal insulin ordinarily does not. Fetal insulin then promotes adiposity and organ growth, while persisting insulin after cord clamping predisposes to neonatal hypoglycaemia.
[2]

Placental hormones, adipokines and inflammatory mediators progressively reduce maternal insulin sensitivity. In normal pregnancy, beta-cell secretion rises to compensate. GDM develops when underlying beta-cell reserve and insulin sensitivity cannot meet that demand. This is a relative failure of compensation; placental hormones do not necessarily cause an absolute decline in insulin output.[2]

Maternal glucose crosses the placenta, whereas maternal insulin ordinarily does not. Fetal hyperglycaemia stimulates fetal insulin secretion. Fetal insulin is anabolic, increasing adiposity and organ growth; after cord clamping, persistent insulin with abrupt loss of maternal glucose creates neonatal hypoglycaemia risk.[2][3]

Maternal

  • Gestational hypertension and pre-eclampsia
  • Operative birth and birth-trauma risk
  • Future type 2 diabetes and recurrent GDM

Fetal / birth

  • Large-for-gestational-age growth and disproportionate adiposity
  • Shoulder dystocia and related injury
  • Stillbirth risk when disease is poorly controlled or complicated

Neonatal

  • Hypoglycaemia
  • Respiratory and metabolic morbidity
  • Hyperbilirubinaemia and NICU admission

Long term

  • Maternal cardiometabolic risk
  • Higher offspring obesity and dysglycaemia risk
  • Metformin-exposed offspring data remain incomplete
[3] [12]

Treatment changes outcomes, but cite the endpoint correctly. In ACHOIS, the serious perinatal composite was 1% with intervention versus 4% with routine care, with more induction but similar caesarean rates. In the MFMU mild-GDM trial, the primary composite was not significantly different (32.4% vs 37.0%), but treatment reduced large-for-gestational-age birth (7.1% vs 14.5%), birthweight above 4 kg (5.9% vs 14.3%), shoulder dystocia (1.5% vs 4.0%), caesarean birth (26.9% vs 33.8%) and combined pre-eclampsia/gestational hypertension (8.6% vs 13.6%).[4][5]

5. Initial management: nutrition, activity and monitoring

Management begins promptly with a diabetes-in-pregnancy team. Individualise medical nutrition therapy to cultural food patterns, adequate maternal/fetal nutrition and appropriate gestational weight gain; spread carbohydrate intake to reduce peaks and avoid severe restriction or ketosis. There is no universal carbohydrate percentage, calorie reduction or mandatory bedtime snack for every patient.[9][15]

If no obstetric contraindication exists, advise regular moderate physical activity—for example about 30 minutes on most days—with post-meal walking as a practical option. Teach self-monitoring at times that answer a treatment question, usually fasting and after meals, and review the pattern rather than reacting to one isolated value.[9][15]

HbA1c is not the routine diagnostic test for GDM and can miss postprandial hyperglycaemia. Continuous glucose monitoring may help selected patients, especially when insulin profiles are difficult to interpret, but it does not replace the named diagnostic test or establish one universal GDM time-in-range target.[15]

6. Pharmacotherapy is regional

FigureLifestyle and glucose review are common foundations, but medication order is regional. ADA/ACOG prefer insulin; NICE usually offers metformin after 1 to 2 weeks, with defined immediate-insulin exceptions. Fetal testing and birth timing depend on control and treatment. Postpartum testing also differs between ADA and NICE.
Sources: ADA 2026 and NICE NG3.[6][9][15]

US — ADA / ACOG

Insulin is preferred first-line pharmacotherapy when lifestyle is insufficient. It does not ordinarily cross the placenta, and the regimen is selected from the glucose pattern: basal insulin for fasting elevation, mealtime insulin for postprandial elevation, or both. Do not copy a universal unit/kg dose or titration schedule; pregnancy stage, body size, glucose pattern, hypoglycaemia and local formulary all matter. Metformin and glyburide cross the placenta and are not preferred first-line agents. ADA 2026 also advises avoiding metformin when hypertension or pre-eclampsia is present or fetal growth restriction/placental insufficiency is a concern because of growth-restriction and acidosis concerns.[9][15]

UK — NICE

If targets are not met with diet and exercise within 1 to 2 weeks, NICE NG3 offers metformin; offer insulin if metformin is contraindicated or unacceptable, and add insulin if metformin plus lifestyle remains insufficient. NG3 names fasting-glucose levels at which insulin should be offered immediately, or considered immediately when macrosomia or hydramnios coexist—follow NG3 for those exact thresholds rather than generalising them into a global insulin rule. Metformin and insulin are both established GDM pharmacotherapies, evaluated head-to-head in randomised trials.[6][7]

[6]

Metformin lowers hepatic glucose production and improves insulin sensitivity but crosses the placenta. In MiG, the composite neonatal outcome was similar (32.0% metformin vs 32.2% insulin); 46.3% allocated metformin required supplemental insulin, and treatment preference favoured metformin (76.6% vs 27.2%). MiG-TOFU provides actual GDM offspring follow-up, but heterogeneous 7-to-9-year findings do not establish complete long-term equivalence. Glyburide also crosses the placenta and meta-analysis found less favourable neonatal outcomes than insulin or metformin; it is not a default substitute.[6][7][12]

7. Fetal surveillance, growth and birth

Separate growth assessment from antenatal wellbeing testing. NICE NG3 offers ultrasound assessment of fetal growth and amniotic fluid at 28, 32 and 36 weeks. In US practice, medication-treated or poorly controlled GDM commonly prompts NST/BPP surveillance from about 32 weeks, while there is no consensus that well-controlled diet-only GDM requires routine testing before 40 weeks. Individualise for hypertension, growth abnormality, reduced movements and other obstetric indications.[9]

Delivery timing is also regional. NICE NG3 advises birth no later than 40+6 weeks for uncomplicated GDM and earlier birth when maternal or fetal complications arise. ACOG generally avoids delivery before 39+0 for well-controlled diet-only GDM and allows expectant management to 40+6; for well-controlled medication-treated GDM, 39+0 to 39+6 is usual. Poor control or complications require individualised earlier planning.[9]

Estimated fetal weight is imprecise. When fetal overgrowth is suspected near term, an estimated fetal weight above 4,500 g is a trigger for counselling about individualised perinatal risk and the potential benefits and harms of scheduled caesarean birth—not an automatic operation. Mode of birth also depends on prior births, pelvis, labour progress, patient preferences and local guidance.[19]

8. Intrapartum care

Document a labour plan before birth. During labour and birth, monitor maternal glucose according to the named local intrapartum protocol and treat toward that protocol's target range, using intravenous dextrose and insulin if oral intake cannot maintain control. This is not a mandate for a fixed insulin-dextrose regimen in every insulin-treated patient, and maternal hypoglycaemia must be avoided.[9]

Prepare for shoulder dystocia when fetal size is high, but do not attempt a prophylactic manoeuvre. Use standard team rehearsal and HELPERR if shoulder dystocia occurs. Active management of the third stage follows obstetric indication; GDM does not replace routine haemorrhage-risk assessment.[9]

9. Newborn care

Tell the neonatal team before birth. NICE NG3 advises skin-to-skin contact, feeding as soon as possible and within 30 minutes, then every 2 to 3 hours, with routine neonatal glucose testing at 2 to 4 hours. Separately, the BAPM 2024 neonatal framework specifies measuring glucose before the second feed (2 to 4 hours); subsequent timing and thresholds follow the local at-risk newborn pathway.[17]

Also assess temperature, respiratory status, jaundice and feeding. Do not delay escalation for jitteriness, lethargy, poor feeding, apnoea or seizures while debating one numerical threshold; follow the BAPM/local neonatal pathway.[17]

10. Postpartum, prevention and future pregnancy

Stop glucose-lowering medication used only for GDM after birth, check maternal glucose before discharge, and investigate persistent hyperglycaemia as possible diabetes, as specified in NICE NG3 and ADA 2026. Insulin needs fall rapidly after placental delivery, but never stop treatment automatically if overt diabetes is suspected or confirmed.[15]

US — ADA

ADA 2026 recommends testing for persistent dysglycaemia early in the postpartum period and ongoing lifelong screening thereafter; follow the linked standard for its named test and intervals. Prediabetes prompts intensive lifestyle support; metformin can be discussed for selected high-risk people, including those with prior GDM, rather than prescribed universally.[15][13][14]

UK — NICE

[15]

NICE NG3 recommends fasting plasma glucose at 6 to 13 weeks. If testing occurs after 13 weeks, offer fasting plasma glucose; use HbA1c only when a fasting test is not possible. Do not routinely offer a postpartum OGTT in the NICE pathway. If the result excludes diabetes, offer annual HbA1c and reinforce prevention.[15]

[15]

A systematic review and meta-analysis found prior GDM associated with an almost 10-fold higher subsequent type 2 diabetes risk, while absolute risk varies with follow-up and population.[16] DPP/DPPOS data support structured lifestyle intervention and, for selected people with prediabetes and prior GDM, metformin after shared decision-making. Avoid promising that one fixed percentage of weight loss “halves” every person's risk.[13][14]

Support breastfeeding, weight optimisation without crash dieting, regular activity and cardiovascular-risk review. Discuss contraception and pregnancy timing. Before another pregnancy, review glucose status and medicines; in the next pregnancy arrange early testing for overt diabetes and repeat routine 24-to-28-week testing if the early result is normal, following NICE NG3 or the named local pathway. Prior GDM or PCOS does not justify universal metformin prophylaxis during pregnancy.[15]

11. Exam pearls

  • WHO/IADPSG: 75 g OGTT, any one of ≥5.1/≥10.0/≥8.5 mmol/L.[8]
  • Two-step US practice: 50 g 1-hour screen, then a 100 g 3-hour OGTT, usually needing two abnormal values.[18]
  • NICE NG3: risk factors lead directly to a diagnostic OGTT—quote NG3's own thresholds rather than importing another pathway's.
  • Treatment targets differ between pathways—quote the named local pathway's published values.
  • ADA/ACOG prefer insulin; NICE NG3 usually offers metformin after a short lifestyle trial, with immediate-insulin exceptions.[9]
  • Suspected fetal weight above 4,500 g triggers counselling about scheduled caesarean, not an automatic operation.[19]
  • BAPM 2024: neonatal 40% dextrose gel 200 mg/kg is approximately 0.5 mL/kg; IV glucose follows the neonatal protocol.[17]
  • Postpartum testing differs by pathway—follow ADA 2026 and NICE NG3 for the named tests and timing.[15]
A region-safe GDM answer — 'NAME IT'

NAMEIT

  • NName the guidelineWHO/IADPSG, ACOG or NICE
  • AAssess overt diabetesseparate pre-existing disease from GDM
  • MMonitor patternsfasting and post-meal values using local targets
  • EEscalate regionallyinsulin-preferred US; metformin-first NICE with exceptions
  • IIndividualise birthcontrol, medication, growth and obstetric factors
  • TTest after pregnancyADA 4–12-week OGTT; NICE 6–13-week fasting glucose
[9] [15]

The mnemonic's UK and US branches are sourced to NICE NG3 and ADA 2026.[15]

References19Show
  1. [1]Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy Diabetes Care, 2010.PMID 20190296
  2. [2]Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus Int J Mol Sci, 2018.PMID 30373146
  3. [3]Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes N Engl J Med, 2008.PMID 18463375
  4. [4]Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes N Engl J Med, 2005.PMID 15951574
  5. [5]Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes N Engl J Med, 2009.PMID 19797280
  6. [6]Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes N Engl J Med, 2008.PMID 18463376
  7. [7]Balsells M, García-Patterson A, Solà I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis BMJ, 2015.PMID 25609400
  8. [8]Sacks DA, Hadden DR, Maresh M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria Diabetes Care, 2012.PMID 22355019
  9. [9]ACOG. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus Obstet Gynecol, 2018.PMID 29370047
  10. [10]ACOG. ACOG Clinical Practice Update: Screening for Gestational and Pregestational Diabetes in Pregnancy and Postpartum Obstet Gynecol, 2024.PMID 42131962
  11. [11]Simmons D, Immanuel J, Hague WM, et al. Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy N Engl J Med, 2023.PMID 37144983
  12. [12]Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age BMJ Open Diabetes Res Care, 2018.PMID 29682291
  13. [13]Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions J Clin Endocrinol Metab, 2008.PMID 18826999
  14. [14]Aroda VR, Christophi CA, Edelstein SL, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up J Clin Endocrinol Metab, 2015.PMID 25706240
  15. [15]American Diabetes Association Professional Practice Committee for Diabetes. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026 Diabetes Care, 2026.PMID 41358885
  16. [16]Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis BMJ, 2020.PMID 32404325
  17. [17]Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial Lancet, 2013.PMID 24075361
  18. [18]Vandorsten JP, Dodson WC, Espeland MA, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus NIH Consens State Sci Statements, 2013.PMID 23748438
  19. [19]Raio L, Ghezzi F, Di Naro E, et al. Perinatal outcome of fetuses with a birth weight greater than 4500 g: an analysis of 3356 cases Eur J Obstet Gynecol Reprod Biol, 2003.PMID 12860334
Gestational Diabetes Mellitus · NeetVellum